JPRN-jRCT2080220768未知1 期
A Randomized, Single-Blind, Placebo-Controlled, Multi-Centre, PhaseI Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 30age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •A body mass index (BMI) of 18 to 27 kg/m2.
- •- Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment.
排除标准
- •- Renal dysfunction GFR <60mL/min.
- •- Systolic pressure (SBP) >160mmHg or diastolic pressure (DBP) >95mmHg.
- •- Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP.
- •- History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.
研究者
相似试验
招募中
3 期
A study to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)Myelin oligodendrocyte glycoprotein (MOG)antibody-associated disease (MOG-AD)JPRN-jRCT2021210052MATSUO TETSUO11
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes (39039039ACS2001)The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome) - The ATLAS ACS TIMI 46 TrialMedDRA version: 8.1Level: LLTClassification code 10051592Term: Acute coronary syndromeAcute Coronary SyndromeEUCTR2006-004449-40-SEBayer HealthCare AG6,625
招募中
1 期
Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingMedDRA version: 20.0Level: PTClassification code: 10013801Term: Duchenne muscular dystrophy Class: 100000004850Duchenne muscular dystrophyCTIS2023-510351-31-00Dyne Therapeutics Inc.75
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes (39039039ACS2001)The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome) - The ATLAS ACS TIMI 46 TrialMedDRA version: 8.1Level: LLTClassification code 10051592Term: Acute coronary syndromeAcute Coronary SyndromeEUCTR2006-004449-40-BGBayer HealthCare AG5,000
进行中（未招募）
1 期
Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-005478-24-IEDyne Therapeutics, Inc112